Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis
Michihito Sato, Kumiko Ohtsuka, Ryo Takahashi, Kuninobu Wakabayashi, Tsuyoshi Odai, Takeo Isozaki, Nobuyuki Yajima, Yusuke Miwa, Tsuyoshi KasamaDivision of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanObjective: To examine the relationship between serum chem...
Guardado en:
Autores principales: | Michihito Sato, Kumiko Ohtsuka, Ryo Takahashi, et al |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7c2f8c664c644d5296fad4e2e0c284d6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Optimal dose of etanercept in the treatment of rheumatoid arthritis
por: Curtis EM, et al.
Publicado: (2014) -
Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis
por: Takeo Isozaki, et al.
Publicado: (2010) -
Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Franz Thiele, et al.
Publicado: (2021) -
Rheumatoid arthritis: Disease or syndrome?
por: Jessica A Stanich, et al.
Publicado: (2009) -
Early activation of the cardiac CX3CL1/CX3CR1 axis delays β-adrenergic-induced heart failure
por: M. Flamant, et al.
Publicado: (2021)